Once-weekly antidiabetic agonist is launched, what is its marketability in Korea?

Since Trulicity, a Lilly’s once-weekly antidiabetic agent, a GLP-1 receptor agonist, acquired product approval, the industry has turned attention from daily treatments to weekly treatments.

Particularly, as Hanmi Pharm has recently transferred the monthly – at the longest – GLP-1 receptor agonist(efpeglenatide) technology to Sanofi, weekly- or monthly-administered GLP-1 agonists have attracted...